Innate Pharma (IPHA) EBITDA Margin (2020 - 2024)
Innate Pharma (IPHA) reported EBITDA Margin of 423.44% for Q4 2024, down 40531.0% on a YoY basis from N/an in Q1 2024, and down 33.45% quarter-over-quarter from 317.29% in Q2 2024.
Innate Pharma (IPHA) EBITDA Margin (2020 - 2024) Analysis & Trends
Innate Pharma has reported EBITDA Margin for 5 years, with the latest figure at 423.44% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin fell 40531.0% year-over-year to 423.44%; the trailing twelve-month figure through Dec 2024 stood at 82.23% (down 4622.0% YoY), and the FY2025 full-year result was 1937.85%, down 168153.0% from the prior year.
- EBITDA Margin for Q4 2024 stood at 423.44%, down from 317.29% in the prior quarter.
- The five-year high for EBITDA Margin was 0.11% in Q4 2022, with the low at 423.44% in Q4 2024.
- Historically, EBITDA Margin has averaged 138.17% across 5 years, with a median of 18.12% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin jumped 19349 bps — and 2024, when it tumbled 40531 bps.
- Innate Pharma's EBITDA Margin stood at 13.52% in 2020, then plunged by 1332 bps to 193.6% in 2021, then surged by 100 bps to 0.11% in 2022, then plunged by 16412 bps to 18.12% in 2023, then sank by 2237 bps to 423.44% in 2024.
- The last three EBITDA Margin figures came in at 423.44% (Q4 2024), 317.29% (Q2 2024), and 18.12% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -423.44% |
| Jun 30, 2024 | -317.29% |
| Dec 31, 2023 | -18.12% |
| Jun 30, 2023 | -1.13% |
| Dec 31, 2022 | -0.11% |
| Dec 31, 2021 | -193.60% |
| Dec 31, 2020 | -13.52% |